CN109223809A - A kind of quinoa astragalin composition and its application in terms of antimicrobial agent - Google Patents
A kind of quinoa astragalin composition and its application in terms of antimicrobial agent Download PDFInfo
- Publication number
- CN109223809A CN109223809A CN201811230331.9A CN201811230331A CN109223809A CN 109223809 A CN109223809 A CN 109223809A CN 201811230331 A CN201811230331 A CN 201811230331A CN 109223809 A CN109223809 A CN 109223809A
- Authority
- CN
- China
- Prior art keywords
- quinoa
- saponin
- antimicrobial agent
- drug
- concentrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of quinoa astragalin composition and its applications in terms of antimicrobial agent, belong to medicine and cosmetic technical field, quinoa astragalin composition of the invention, it is made of one or more saponin compounds, it is obtained and being extracted to quinoa wheat bran, it is experimentally confirmed, the rat that quinoa astragalin composition infects staphylococcus aureus and staphylococcus epidermis all has apparent bacteriostasis, it can promote the healing of rat surface wound, improve survival rate, it can be applied to drug-resistance bacteria medicine and cosmetics, realize the higher value application of quinoa wheat bran.
Description
Technical field
The present invention relates to medicine and cosmetic technical fields, and in particular to a kind of quinoa astragalin composition and its in overriding resistance
Application in terms of bacterium.
Background technique
Currently, people pay more attention to nutrient health problem, quinoa as a kind of very high cereal crops of nutritive value, by
It is progressive enter people the visual field, FAO (Food and Agriculture Organization of the United Nation) be even more formal recommendation quinoa be the optimum mankind wholefood.Due to
Quinoa wheat bran bitter is not suitable as feed and uses and largely abandoned, causes a large amount of wasting of resources, and quinoa saponin(e exists
It is all distributed in entire plant, but in the main papilla cell for being present in outer kind of the shell of kind of grain, with abandoning for quinoa wheat bran
The chance being not used.
Drug-fast bacteria refers to the pathogen with drug resistance.Occur after long-term antibiotic selection to corresponding antibiotic
The microorganism of tolerance is generated, drug-fast bacteria is referred to as.The drug resistance of so-called bacterium refers to bacterium repeatedly and after medicament contact, right
The sensibility of drug, which reduces, even to disappear, and causes drug to reduce the curative effect of drug-fast bacteria even invalid.
At present about the research of saponin(e component in quinoa wheat bran it has been reported that still quinoa saponin(e is in terms of antimicrobial agent
Application study is relatively fewer, especially in the concrete application of the medicine of antimicrobial agent and cosmetics.
Summary of the invention
The present invention provides a kind of quinoa astragalin composition and its application in terms of antimicrobial agent, quinoa astragalin composition from
It extracts and obtains in quinoa wheat bran, the saponin compound comprising one or more different structures has drug-fast bacteria good antibacterial
Effect can be applied to drug and cosmetics that preparation has antimicrobial agent, realize the higher value application of quinoa wheat bran.
The technical solution adopted by the invention is as follows:
A kind of quinoa astragalin composition is made of, the saponin compound any one or more following saponin compound
Mother nucleus structure it is as follows:
Wherein, R1、R2、R3、R4The group and its connection type of representative are as follows, and serial number 1-6 indicates six kinds of different structures
Saponin compound:
The invention also includes a kind of drug for antimicrobial agent, the drug includes that quinoa saponin(e described above combines
Object.
Preferably, the pharmaceutical dosage form is pharmaceutically acceptable dosage form, including tablet, paste, emulsion, ointment,
Detergent, liquid preparation.
The invention also includes a kind of cosmetics for antimicrobial agent, the toiletry bag is containing quinoa saponin(e described above
Composition.
Preferably, the State of cosmetics includes skin softening toner, Firm toner, nutrition toner, nourishing cream, massage
Cream, essence, eye cream, eye essence, facial mask, loose powder, lotion, skin cream, soothing oil, skin essence, shampoo, hair care
Element, scalp curing agent, shower cream, perfumed soap, facial cleanser, makeup remover, make-up remover or makeup removing gel.
The invention also includes the application of quinoa astragalin composition described above in the drug for preparing antimicrobial agent.
The invention also includes the application of quinoa astragalin composition described above in the cosmetics for preparing antimicrobial agent.
The present invention also provides a kind of preparation methods of quinoa saponin compound, comprising the following steps: by the quinoa bran of crushing
Skin is extracted with ethyl alcohol and by extracting solution filtering and concentrating, is successively cleaned to concentrate with petroleum ether, ethyl acetate, then with just
Butanol, before immunoassay and concentrated by rotary evaporation extract liquor, drying obtain the quinoa saponin(e slightly mentioned, then get required quinoa through rough segmentation, essence
Saponin(e.
Preferably, specifically includes the following steps:
(1) it extracts: quinoa wheat bran is crushed, cross 40 meshes, 75% ethyl alcohol of 8-10 times of weight, the shake of room temperature ultrasound is added
40min is swung, standing two hours obtains extracting solution；
(2) it is concentrated: extracting solution is filtered, then filtrate is rotated and removes most of ethyl alcohol, obtain concentrate；
(3) it cleans: the petroleum ether of 2 times of volumes being added into concentrate, concussion layering removes petroleum ether layer, adds 2 times
The ethyl acetate of volume, concussion layering, removes ethyl acetate layer；
(4) it extracts: the n-butanol layer of 2 times of volumes is added, extract 2-3 times, stratification takes n-butanol layer, revolves in 60 DEG C
Inspissation contracting, obtains quinoa saponin(e crude extract concentrate；
(5) it dries: concentrate obtained above being placed in 60 DEG C of water-baths and is dried, saponin(e is slightly mentioned；
(6) rough segmentation: largely being separated using large-scale large pore resin absorption column, and the mixed liquor of second alcohol and water is elution system
System carries out gradient elution to it, obtains the saponin(e of a large amount of rough segmentation；
(7) it essence point: is precisely separated using C18 reversed-phase liquid chromatography column, obtains required quinoa saponin(e.
Beneficial effects of the present invention are shown: the six kinds of saponin compounds chosen in quinoa astragalin composition are in quinoa wheat bran
In content it is higher, convenient for extracting and preparation, and its mother nucleus structure is similar, and all has certain bacteriostasis；By to Chenopodiaceae
Wheat bran skin saponin extraction condition optimizes, and can quickly and efficiently extract saponin compound；It is experimentally confirmed, quinoa saponin(e pair
Staphylococcus aureus and the rat of staphylococcus epidermis infection all have apparent bacteriostasis, and rat body surface can be promoted to hurt
The healing of mouth improves survival rate, can be applied to drug-resistance bacteria medicine and cosmetics, realize the higher value application of quinoa wheat bran.
Specific embodiment
In order to facilitate the understanding of those skilled in the art, the present invention is further illustrated below.
A kind of quinoa astragalin composition is made of, the saponin compound any one or more following saponin compound
Mother nucleus structure it is as follows:
Wherein, R1、R2、R3、R4The group and its connection type of representative are as follows, and serial number 1-6 indicates six kinds of different structures
Saponin compound:
The preparation method of above-mentioned quinoa saponin compound, comprising the following steps:
(1) it extracts: quinoa wheat bran is crushed, cross 40 meshes, 75% ethyl alcohol of 8-10 times of weight, the shake of room temperature ultrasound is added
40min is swung, standing two hours obtains extracting solution；
(2) it is concentrated: extracting solution is filtered, then filtrate is rotated and removes most of ethyl alcohol, obtain concentrate；
(3) it cleans: the petroleum ether of 2 times of volumes being added into concentrate, concussion layering removes petroleum ether layer, adds 2 times
The ethyl acetate of volume, concussion layering, removes ethyl acetate layer；
(4) it extracts: the n-butanol layer of 2 times of volumes is added, extract 2-3 times, stratification takes n-butanol layer, revolves in 60 DEG C
Inspissation contracting, obtains quinoa saponin(e crude extract concentrate；
(5) it dries: concentrate obtained above being placed in 60 DEG C of water-baths and is dried, saponin(e is slightly mentioned；
(6) rough segmentation: largely being separated using large-scale large pore resin absorption column, using the mixed liquor of second alcohol and water to it
Gradient elution is carried out, the saponin(e of a large amount of rough segmentation is obtained；
(7) it essence point: is precisely separated using C18 reversed-phase liquid chromatography column, obtains required quinoa saponin(e.
One, the inhibition drug-fast bacteria growth result of quinoa saponin(e of the present invention is illustrated by antibacterial experiment in vitro.
Specific method: staphylococcus aureus, staphylococcus epidermis, Sharpe bacillus enteritidis and pseudomonas aeruginosa four are used
The common drug-fast bacteria of kind, examines the bacteriostasis of quinoa saponin(e.
Each extract layer is obtained by the preparation method of quinoa saponin compound described above, is n-butanol layer, second respectively
Ethyl acetate layer, petroleum ether layer, each extract layer saponin content be 10mg/mL, with sterling quinoa saponin(e (six kinds of structures), penicillin,
Cefixime is reference substance, and the content of saponin(e is 2mg/mL, and using pure water layer as reference substance；It is (straight that 6 scraps of paper are put in a kind of bacterium
Diameter 5mm), 1,2,3,4,5,6 are put on pencil on the scraps of paper respectively, the n-butanol layer extract of 10 μ L is taken to get on No. 1 scraps of paper,
It takes the n-butyl alcohol extract of 10 μ L to stamp again after the scraps of paper dry, makes a call to altogether 5 times；Petroleum ether layer, ethyl acetate layer and water layer,
N-butyl alcohol extract operation is identical, successively gets on No. 2, No. 3 and No. 4 scraps of paper each 5 times；The penicillin of 10 μ L is taken to get to No. 5 paper
On piece, takes the Cefixime of 10 μ L to get on No. 6 scraps of paper, and the scraps of paper are successively had to a kind of being put on Micro-Organism Culture Dish for spacing.Respectively
The feeding ware of monomer saponin, which is placed in 37 DEG C of constant incubator, cultivates 10-12h, observes around the scraps of paper whether there is or not inhibition zone and measures
The diameter of inhibition zone, experimental result are as shown in table 1 below.
1 quinoa saponin(e bacteriostatic activity test result of table
The results show that n-butanol layer extract is compared to other each layer extracts to staphylococcus aureus and epidermis grape
Coccus has higher inhibiting effect, the fungistatic effect of positive reference substance penicillin and Cefixime is only second to, through verifying just
Butanol layer extract is mainly saponin compound, can provide new approaches for treatment drug resistance bacterial diseases.
Two, quinoa saponin(e acute toxicological experiment.
By carrying out acute toxicological experiment to quinoa saponin(e, whether observation quinoa saponin(e has toxicity, specific experiment method:
50 rats, half male and half female similar in experimental animal selective body weight, are randomly divided into 5 groups, and every group of male and female each five, before experiment
It is deprived of food but not water within 12 hours.
Be arranged four experimental group quinoa astragalin compositions (quinoa astragalin composition contains 60% saponin(e 1,18% saponin(e 2,
13% saponin(e 3,9% saponin(e 4) and a control group, experimental group be divided into four concentration: 100mg/mL, 250mg/mL, 500mg/
ML, 1000mg/mL carry out stomach-filling according to 1ml/100g respectively in equal volume, rat oral gavage dosage be respectively 1g/kg, 2.5g/kg,
5g/kg, 10g/kg, intake are 10 times of normal human's amount of daily intaking, 25 times, 50 times, 100 times, and rat is observed continuously
State 14 days.
Experimental result: high dose group spirit is not good enough after 40 rat oral gavages of experimental group, and diarrhea occur in a small number of rats in part
Phenomenon, stopping in second day restore normal；Occur after fortnight without the phenomena of mortality, rat serum is mutually normal, and tissue is raw without obvious damage
Change each index no significant difference.Prove that saponin(e is nontoxic in human body intake limit range.
Three, staphylococcus aureus, the experiment of staphylococcus epidermis infected rats.
42 rats, half male and half female similar in experimental animal selective body weight are randomly divided into 14 groups, every group 3: model
Group I (infection of staphylococcus aureus), model group II (staphylococcus epidermis infection), the administration group I-VI of six kinds of saponin(es are (golden yellow
Color staphy lococcus infection), the administration group I-VI (staphylococcus epidermis infection) of six kinds of saponin(es.Every rat dorsum skin is taken off
Rat skin is abraded after volatilizing with sand paper using 75% ethanol disinfection and is smeared staphylococcus aureus, epidermis grape respectively by hair
Coccus bacterium solution, is fixed with gauze；After 12 hours, administration group smears the drug 0.5mL (saponin(e for containing different saponin(es in wound respectively
Concentration is that 1.0%), model group smears the excipient that saponin(e is not added in wound, is fixed with gauze, and daily dressing simultaneously observes rat wound
Mouth variation, successive administration 5 days, and observe 8 days.
Experimental result: each administration group rat visible wound in 3 days is shunk, and forms scab, local skin is cured in 4-7 days
It closes, wound all healed in 21 days after wound.Visible inflammation phenomenon near model group rats skin wounds, wound healing is slow, place
In dye state.
Four, concrete application of the quinoa astragalin composition in terms of antimicrobial agent.
Embodiment 1:
A kind of antimicrobial agent externally-applied soft ointment, the ointment are prepared from the following raw materials: quinoa astragalin composition (contains
50% saponin(e 1,21% saponin(e 2,18% saponin(e 3,11% saponin(e 5, and using the preparation method system of above-mentioned quinoa saponin compound
) 2g, matrix auxiliary material 51g, the matrix auxiliary material is prepared from the following raw materials: camellia seed oil 10g, hexadecanol 9g, albolene
10g, liquid paraffin 7g, Tween 80 g, glycerol 5g, purified water 100g.
Specific preparation method: taking camellia seed oil, and hexadecanol, albolene, liquid paraffin is added in 80 ± 5 DEG C of heating water baths；
Purified water 100ml is taken, tween, glycerol is added in 80 ± 5 DEG C of heating water baths；Using homogenizer, under stiring, by oily mutually with thread
Shape is added in water phase, and quinoa astragalin composition is added, then is stirred at room temperature to cooling to get corresponding ointment is arrived.
The externally-applied soft ointment of the antimicrobial agent using quinoa astragalin composition as main active, have inhibit drug-fast bacteria,
Inhibit Tyrosinase, inhibit the effect of melanin production, is a kind of safely and effectively natural plants external cosmetics.
Embodiment 2:
A kind of antimicrobial agent exterior-applied emulsion, the emulsion are prepared from the following raw materials: quinoa astragalin composition (contains 30% soap
Glycosides 2,28% saponin(e 3,18% saponin(e 4,10% saponin(e 5,14% saponin(e 6, and using the preparation side of above-mentioned quinoa saponin compound
Method is made) 2g, matrix auxiliary material 52.1g, the matrix auxiliary material is prepared from the following raw materials: camellia seed oil 10g, hexadecanol 3g, Bai Fan
Intellectual circle 5g, glycerin monostearate 10g, glycerol 20g, sodium hydroxide 0.1g, purified water 100g.
Specific preparation method: taking camellia seed oil, and hexadecanol, albolene, monostearate is added in 80 ± 5 DEG C of heating water baths
Glyceride；Purified water 100ml is taken, sodium hydroxide, glycerol is added in 80 ± 5 DEG C of heating water baths；It, under stiring, will using homogenizer
It is oily to be mutually added in water phase with thread shape, quinoa astragalin composition is added, then be stirred at room temperature to cooling to get corresponding cream is arrived
Agent.
The exterior-applied emulsion of the antimicrobial agent has the function for inhibiting drug-fast bacteria using quinoa astragalin composition as main active
Effect is a kind of safely and effectively natural plants topical drug.
Embodiment 3:
A kind of antimicrobial agent externally used paste, the paste are prepared from the following raw materials: quinoa astragalin composition (contains 20% soap
Glycosides 1,21% saponin(e 2,17% saponin(e 3,10% saponin(e 4,20% saponin(e 5,12% saponin(e 6, and use above-mentioned quinoa saponin(e chemical combination
The preparation method of object is made) 2g, matrix auxiliary material 53g, the matrix auxiliary material is prepared from the following raw materials: camellia seed oil 10g, hexadecanol
2g, stearic acid 12g, glycerin monostearate 1g, glycerol 20g, sodium hydroxide 0.1g, potassium hydroxide 0.4g, purified water 100g.
Specific preparation method: taking camellia seed oil, and it is sweet that hexadecanol, stearic acid, monostearate is added in 80 ± 5 DEG C of heating water baths
Grease；Purified water 100ml is taken, sodium hydroxide, potassium hydroxide, glycerol is added in 80 ± 5 DEG C of heating water baths；Using homogenizer, stirring
It mixes down, is mutually added to oily in water phase with thread shape, quinoa astragalin composition is added, then be stirred at room temperature to cooling to get arriving
Corresponding paste.
The exterior-applied emulsion of the antimicrobial agent has the function for inhibiting drug-fast bacteria using quinoa astragalin composition as main active
Effect is a kind of safely and effectively natural plants topical drug.
Above content is only to structure example of the invention and explanation, affiliated those skilled in the art
It makes various modifications or additions to the described embodiments or is substituted in a similar manner, without departing from invention
Structure or beyond the scope defined by this claim, be within the scope of protection of the invention.
Claims (9)
1. a kind of quinoa astragalin composition is made of, which is characterized in that the soap any one or more following saponin compound
The mother nucleus structure of glycoside compound is as follows:
Wherein, R1、R2、R3、R4The group and its connection type of representative are as follows, and serial number 1-6 indicates the soap of six kinds of different structures
Glycoside compound:
。
2. a kind of drug for antimicrobial agent, which is characterized in that the drug includes quinoa saponin(e as described in claim 1
Composition.
3. a kind of drug for antimicrobial agent according to claim 2, which is characterized in that the pharmaceutical dosage form is pharmacy
Upper acceptable dosage form, including tablet, paste, emulsion, ointment, detergent, liquid preparation.
4. a kind of cosmetics for antimicrobial agent, which is characterized in that the toiletry bag contains quinoa as described in claim 1
Astragalin composition.
5. a kind of cosmetics for antimicrobial agent according to claim 4, which is characterized in that the State of cosmetics packet
It includes skin softening toner, Firm toner, nutrition toner, nourishing cream, massage cream, essence, eye cream, eye essence, facial mask, dissipate
Powder, skin cream, soothing oil, skin essence, shampoo, hair conditioner, scalp curing agent, shower cream, perfumed soap, is washed one's face at lotion
Milk, makeup remover, make-up remover or makeup removing gel.
6. application of the quinoa astragalin composition according to claim 1 in the drug for preparing antimicrobial agent.
7. application of the quinoa astragalin composition according to claim 1 in the cosmetics for preparing antimicrobial agent.
8. a kind of preparation method of quinoa saponin compound described in claim 1, which comprises the following steps: will
The quinoa wheat bran of crushing is extracted with ethyl alcohol and by extracting solution filtering and concentrating, is successively carried out to concentrate with petroleum ether, ethyl acetate
Removal of impurities, then with extracting n-butyl alcohol and concentrated by rotary evaporation extract liquor, drying obtains the quinoa saponin(e slightly mentioned, then through rough segmentation, essence point
Obtain required quinoa saponin(e.
9. the preparation method of quinoa saponin compound according to claim 8, which is characterized in that specifically include following step
It is rapid:
(1) it extracts: quinoa wheat bran is crushed, cross 40 meshes, 75% ethyl alcohol of 8-10 times of weight, room temperature ultrasonic vibration is added
40min, standing two hours obtains extracting solution；
(2) it is concentrated: extracting solution is filtered, then filtrate is rotated and removes most of ethyl alcohol, obtain concentrate；
(3) it cleans: the petroleum ether of 2 times of volumes being added into concentrate, concussion layering removes petroleum ether layer, adds 2 times of volumes
Ethyl acetate, concussion layering, remove ethyl acetate layer；
(4) it extracts: the n-butanol layer of 2 times of volumes is added, extract 2-3 times, stratification takes n-butanol layer, dense in 60 DEG C of revolvings
Contracting, obtains quinoa saponin(e crude extract concentrate；
(5) it dries: concentrate obtained above being placed in 60 DEG C of water-baths and is dried, saponin(e is slightly mentioned；
(6) rough segmentation: largely being separated using large-scale large pore resin absorption column, is carried out using the mixed liquor of second alcohol and water to it
Gradient elution obtains the saponin(e of a large amount of rough segmentation；
(7) it essence point: is precisely separated using C18 reversed-phase liquid chromatography column, obtains required quinoa saponin(e.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811230331.9A CN109223809A (en) | 2018-10-22 | 2018-10-22 | A kind of quinoa astragalin composition and its application in terms of antimicrobial agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811230331.9A CN109223809A (en) | 2018-10-22 | 2018-10-22 | A kind of quinoa astragalin composition and its application in terms of antimicrobial agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109223809A true CN109223809A (en) | 2019-01-18 |
Family
ID=65080883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811230331.9A Pending CN109223809A (en) | 2018-10-22 | 2018-10-22 | A kind of quinoa astragalin composition and its application in terms of antimicrobial agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109223809A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563408A (en) * | 2021-07-29 | 2021-10-29 | 上海理工大学 | Method for preparing saponin by utilizing chenopodium quinoa and separation and identification method of chenopodium quinoa saponin |
| CN113876824A (en) * | 2021-11-09 | 2022-01-04 | 河北农业大学 | Quinoa saponin and wild chrysanthemum flower composition, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176847A (en) * | 2016-07-06 | 2016-12-07 | 中国农业科学院作物科学研究所 | A kind of have Quinoa saponin strengthening bacteriostasis and preparation method thereof |
-
2018
- 2018-10-22 CN CN201811230331.9A patent/CN109223809A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106176847A (en) * | 2016-07-06 | 2016-12-07 | 中国农业科学院作物科学研究所 | A kind of have Quinoa saponin strengthening bacteriostasis and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| WOLDEMICHAEL GM等: "Identification and biological activities of triterpenoid saponins from Chenopodium quinoa", 《J AGRIC FOOD CHEM》 * |
| 胡一晨等: "藜麦活性成分研究进展", 《作物学报》 * |
| 金茜等: "我国藜麦籽实的研究与开发利用进展", 《食品科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113563408A (en) * | 2021-07-29 | 2021-10-29 | 上海理工大学 | Method for preparing saponin by utilizing chenopodium quinoa and separation and identification method of chenopodium quinoa saponin |
| CN113876824A (en) * | 2021-11-09 | 2022-01-04 | 河北农业大学 | Quinoa saponin and wild chrysanthemum flower composition, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI746492B (en) | An accelerator that promotes the production of glycerol derived from Staphylococcus epidermidis, an accelerator that promotes the production of antibacterial peptides derived from keratinocytes of the skin, and the use of external agents for skin protection | |
| US4382886A (en) | Method for extracting propolis and water soluble dry propolis powder | |
| CN109078165B (en) | Composition for nursing female private parts and preparation method and application thereof | |
| KR101864409B1 (en) | Antibacterial or antifungal composition comprising oriental medicine extract and microbial ferment extract as an active ingredient | |
| CN108524866A (en) | A kind of Traditional Chinese medicine bacteriostatic gelling agent and preparation method thereof | |
| CN102028644A (en) | Bathing article based on medicinal property of related extraction parts of mugwort | |
| CN102836367A (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| CN109893475A (en) | Antibacterial comprising botanical extract mixture, anti-inflammatory, anti-oxidant, sebum secretion inhibits and dermatitis improvement composition | |
| CN109223809A (en) | A kind of quinoa astragalin composition and its application in terms of antimicrobial agent | |
| CN111297961A (en) | Dong medicine for promoting wound healing | |
| CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
| CN1201676A (en) | Cosmetical face film with Chinese medicines | |
| KR101302678B1 (en) | Antifungal compositions containing camellia japonica extracts | |
| KR101231158B1 (en) | An antibacterial and antifungal composition containing the extracts and fractions of Hosta capitata as active ingredient | |
| CN103007258A (en) | Medical composition containing fish serine protease and antibacterial compound, and uses thereof | |
| CN104985963A (en) | Novel stationery storage device compounded by tourmaline and activated carbon | |
| KR20170141564A (en) | Cosmetic composition containing propolis and extracts of opuntia humifusa | |
| JP2001139489A (en) | Cosmetic composition | |
| CN114306526A (en) | Compound broadleaf holly leaf traditional Chinese medicine extract and application thereof in preparing shower gel or hand sanitizer | |
| CN106860188A (en) | Beauty moisturizing nanometer creams | |
| KR102488864B1 (en) | Composition Containing Terminalia Chebula Extract and Artemisia Extract for Controlling Skin Bacterial Flora Growth, or Enhancing Skin Immunity | |
| CN103341044B (en) | Itching-relieving compound preparation and preparation method thereof | |
| CN113388460A (en) | Faint scent type perfumed soap containing peony flowers and preparation method thereof | |
| CN101780179B (en) | Multifunctional plant composition and application thereof as well as multifunctional plant extractive composition, application and antibiotic composition thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |